AI Article Synopsis
- Neuroblastoma is a challenging pediatric cancer, resistant to many treatments, prompting investigation of TAE226, a new small molecule FAK inhibitor.
- In vitro experiments showed that TAE226 significantly reduces FAK phosphorylation, lowers cell viability, causes cell cycle arrest, and increases apoptosis in neuroblastoma cell lines.
- The findings suggest that targeting FAK could be a promising therapeutic strategy for neuroblastoma, warranting further research.
Article Abstract
Purpose: Neuroblastoma is one of the most devastating pediatric solid tumors and is unresponsive to many interventions. TAE226 is a novel small molecule FAK inhibitor. We investigated the effects of TAE226 on neuroblastoma cells in vitro.
Materials And Methods: Human neuroblastoma cell lines were treated with varying concentrations of TAE226. Following treatment, cell viability, cell cycle, and apoptosis were evaluated.
Results: Treatment of human neuroblastoma cell lines with TAE226 resulted in a concentration dependent decrease in FAK phosphorylation, decrease in cellular viability, cell cycle arrest, and an increase in apoptosis.
Conclusions: Targeting FAK provides potential therapeutic options for the treatment of neuroblastoma and deserves further investigation.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/07357900701577475 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!